文献速递炎症性肠病

蠕形螨病模拟接受Upadacitinib治疗的炎症性肠病患者的痤疮样皮疹

Demodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib.
PubMed 文献 · Am J Gastroenterol · 2025-10-22

该研究纳入509例炎症性肠病(IBD)患者,其中30例出现痤疮样皮疹,20例检出蠕形螨病。所有蠕形螨病患者均成功治疗且无需调整IBD治疗。Upadacitinib使用是蠕形螨病的唯一独立危险因素,18例暴露者中16例发生。

要点

  • IBD患者出现痤疮样皮疹时应考虑蠕形螨病,尤其使用Upadacitinib者。
  • Upadacitinib暴露者中蠕形螨病发生率高(18例中16例)。
  • 蠕形螨病可成功治疗而无需调整IBD治疗。

核心结论

  • IBD患者出现痤疮样皮疹时应考虑蠕形螨病,尤其是接受Upadacitinib治疗者。

研究设计与样本

  • 2019至2021年,509例IBD患者中因痤疮样皮疹转诊皮肤科评估,按蠕形螨病状态比较。

主要发现

  • 509例IBD患者中30例出现痤疮样皮疹,其中20例检出蠕形螨病。
  • 所有蠕形螨病患者均成功治疗,无需调整IBD治疗。
  • Upadacitinib使用是蠕形螨病的唯一独立危险因素,18例暴露者中16例发生。

临床怎么用

  • 对IBD患者出现痤疮样皮疹,尤其使用Upadacitinib者,应评估蠕形螨病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acne is a common side effect of inflammatory bowel disease (IBD) treatment. We investigated the role of demodicosis in acne development in patients with IBD. METHODS: From 2019 to 2021, IBD patients with acneiform eruptions were referred for dermatological evaluation. We compared these patients according to the demodicosis status. RESULTS: Of 509 patients with IBD, 30 had acneiform eruptions. Among them, 20 had demodicosis. All were successfully treated without IBD treatment adjustments. Upadacitinib use was the only independent risk factor of demodicosis, occurring in 16 of 18 exposed patients. DISCUSSION: Demodicosis should be considered in patients with IBD having acneiform eruptions, particularly those receiving upadacitinib.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wu HY, Yang CY, Weng MT, et al. Demodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib. Am J Gastroenterol. 2025. PMID: 41123389. doi:10.14309/ajg.0000000000003813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。